The DES phase is complete (data previously presented at ASCO 2019). Female patients with high-grade ovarian cancer (OC) enrolled with nearly all lines of systemic therapy. Patient characteristics included a median age of 66 years and a median performance status of 0. Most TRAEs were Grade 1 or 2. Serious TRAEs were Grade 3 or 4 and most were Grade 3. No ≥Grade 3 (severe) neutropenia, peripheral neuropathy, or neurotoxicity was observed. Of the 27 patients with OC, 20 were evaluable at the time of data cut. SAEs have been reported in 10 (29%) patients. Most TRAEs were Grade 1 or 2. No ≥Grade 3 (severe) neutropenia, peripheral neuropathy, or neurotoxicity was observed. Of the 27 patients with OC, 20 were evaluable at the time of data cut. SAEs have been reported in 10 (29%) patients. Most TRAEs were Grade 1 or 2. No ≥Grade 3 (severe) neutropenia, peripheral neuropathy, or neurotoxicity was observed. Of the 27 patients with OC, 20 were evaluable at the time of data cut. SAEs have been reported in 10 (29%) patients. Most TRAEs were Grade 1 or 2. No ≥Grade 3 (severe) neutropenia, peripheral neuropathy, or neurotoxicity was observed. Of the 27 patients with OC, 20 were evaluable at the time of data cut. SAEs have been reported in 10 (29%) patients. Most TRAEs were Grade 1 or 2. No ≥Grade 3 (severe) neutropenia, peripheral neuropathy, or neurotoxicity was observed.